IND Protocol: Intravenous Artesunate for
Treatment of Severe Malaria in the United States

IND Sponsor: Centers for Disease Control and Prevention (CDC)

CDC IRB #: 5032
IND #: 76,725

Revised February 12, 2019

CONFIDENTIAL - This expanded access IND protocol for Intravenous Artesunate from the Centers for Disease Control and Prevention is to facilitate and allow use of the artesunate product provided specifically with this protocol. It should not be further distributed or its contents used for any other purpose without a prior authorization from the Centers for Disease Control and Prevention.
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>PROGRAM CONTACT INFORMATION</td>
<td>4</td>
</tr>
<tr>
<td>1.0 SUMMARY</td>
<td>5</td>
</tr>
<tr>
<td>2.0 BACKGROUND</td>
<td>5</td>
</tr>
<tr>
<td>3.0 QUINIDINE</td>
<td>7</td>
</tr>
<tr>
<td>4.0 ARTESUNATE</td>
<td>7</td>
</tr>
<tr>
<td>5.0 ARTESUNATE: PRODUCT SOURCE AND DESCRIPTION</td>
<td>13</td>
</tr>
<tr>
<td>6.0 OBJECTIVES</td>
<td>14</td>
</tr>
<tr>
<td>7.0 TREATMENT DESIGN</td>
<td>14</td>
</tr>
<tr>
<td>8.0 ADMINISTRATION OF ARTESUNATE AND FOLLOW-ON TREATMENT</td>
<td>15</td>
</tr>
<tr>
<td>9.0 SUPPORTIVE CARE AND FOLLOW-UP</td>
<td>17</td>
</tr>
<tr>
<td>10.0 SAFETY DATA COLLECTION AND REPORTING</td>
<td>18</td>
</tr>
<tr>
<td>11.0 DATA COLLECTION, HANDLING, AND RECORDKEEPING</td>
<td>20</td>
</tr>
<tr>
<td>12.0 PROGRAM MODIFICATIONS</td>
<td>20</td>
</tr>
<tr>
<td>13.0 PROGRAM RESPONSIBILITIES</td>
<td>20</td>
</tr>
<tr>
<td>14.0 ETHICAL, LEGAL, AND ADMINISTRATIVE REQUIREMENTS</td>
<td>21</td>
</tr>
<tr>
<td>15.0 FINANCING AND INSURANCE</td>
<td>23</td>
</tr>
<tr>
<td>16.0 PUBLICATION POLICY</td>
<td>23</td>
</tr>
<tr>
<td>17.0 REFERENCES</td>
<td>24</td>
</tr>
</tbody>
</table>
APPENDICES

Appendix I  DEMOGRAPHICS
Appendix II  TREATMENT PLAN
Appendix III ADVERSE EVENT REPORT FORM
Appendix IV  LIST OF CDC QUARANTINE STATIONS
Appendix V  PARTICIPANT CONSENT/PARENTAL PERMISSION FORM
PROGRAM CONTACT INFORMATION

Principal Investigators:
Kathrine Tan, M.D.
Chief, Domestic Malaria Unit
Division of Parasitic Diseases and Malaria
Centers for Disease Control and Prevention
1600 Clifton Road NE, MS A-06
Atlanta, GA 30333
Phone: 404.718.4701
Fax: 404.718.4815

Clinical Project Manager:
Kathrine Tan, M.D.

Medical Monitor:
Kathrine Tan, M.D.
1.0 SUMMARY:

Currently, there are no Food and Drug Administration (FDA) approved therapeutics for treatment of severe malaria in the United States (US). Previously, intravenous (IV) quinidine gluconate was the only parenteral drug available in the US that was FDA-approved for the treatment of severe malaria. However, in November 2017, the manufacturer of IV quinidine (Eli Lilly Pharmaceuticals) ceased production of quinidine permanently and remaining stocks of quinidine expired on March 31, 2019. A well proven alternate treatment, recommended by the World Health Organization (WHO) in preference to quinidine and used worldwide for the treatment for severe malaria, is artesunate. Artesunate, however, has not yet been approved by the Food and Drug Administration (FDA) for use in the US. Through an expanded access Investigational New Drug (IND) program, CDC has made IV artesunate available for treatment of severe malaria under an IND protocol with IV artesunate product produced by the Walter Reed Army Institute of Research (WRAIR). We propose to make this intravenous GMP IV artesunate available to malaria patients hospitalized in the US who need IV treatment because of severe disease, high parasitemia, or inability to take oral medications. The drug will be provided to the hospitals, upon request for a patient with severe malaria. The IV artesunate will be followed by oral treatment with atovaquone-proguanil (Malarone), doxycycline, clindamycin, or mefloquine to ensure maximal curative effect. The receiving physicians will be requested to notify CDC of any adverse event following administration of the drug.

2.0 BACKGROUND

2.1 Severe malaria

Severe malaria is a major global health problem. An estimated 440,000 deaths are caused annually by severe malaria, with the majority of deaths occurring in young children (WHO 2017). Severe malaria is a medical emergency whose treatment has become increasingly difficult due to the advent and spread of drug-resistant parasites. This situation has been improved by the introduction of artemisinin derivatives, whose life saving properties reside in their rapid action and their efficacy against multidrug-resistant parasites.

Severe malaria results from the infection of a large number of red blood cells by malaria parasites. Of the four species of malaria parasites that infect humans (Plasmodium falciparum, P. vivax, P. ovale, and P. malariae), almost all cases of severe malaria are due to P. falciparum. There have been rare case reports of severe manifestations of disease associated with P. vivax infection (Kochar 2005).

The large-scale destruction of parasitized red blood cells releases biologic products harmful to the infected host. The sequestration of infected red blood cells in the small vessels of vital organs such as the brain or kidneys leads to end-organ dysfunction. The resulting manifestations of severe malaria include those listed in Table 1.
Table 1: Clinical and laboratory features of severe malaria (WHO 2015)

<table>
<thead>
<tr>
<th>Feature</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cerebral malaria</td>
</tr>
<tr>
<td>Generalized convulsions</td>
</tr>
<tr>
<td>Severe anemia</td>
</tr>
<tr>
<td>Hypoglycemia</td>
</tr>
<tr>
<td>Metabolic acidosis</td>
</tr>
<tr>
<td>Acute renal failure</td>
</tr>
<tr>
<td>Acute pulmonary edema, acute respiratory distress syndrome (ARDS)</td>
</tr>
<tr>
<td>Circulatory shock</td>
</tr>
<tr>
<td>Abnormal bleeding</td>
</tr>
<tr>
<td>Disseminated intravascular coagulation</td>
</tr>
<tr>
<td>Jaundice</td>
</tr>
<tr>
<td>Hemoglobinuria</td>
</tr>
<tr>
<td>High fever</td>
</tr>
<tr>
<td>Hyperparasitaemia</td>
</tr>
</tbody>
</table>

Despite appropriate therapy and medical care, mortality from severe malaria remains high. Case fatality rates were 7.3% - 17.7% in children admitted with severe malaria to a Kenya hospital (Marsh 1995), and 3-15% in European patients admitted in European hospitals (Mühlberger 2003, Krause 2006). The case fatality rate in the United States is estimated to be 1% (Newman 2004).

2.2 Severe malaria in the United States

In the United States malaria is now a rare disease; for this reason it is not always recognized, diagnosed and treated in time and correctly. Annually, there are almost 2000 diagnosed cases of malaria in the US reported to the CDC (CDC 2018). Almost all of these cases occur in persons who, after acquiring the infection in a malaria endemic area abroad, are diagnosed after return to the US (“imported malaria”). Most of these patients are US residents who have no acquired immunity to malaria and are, therefore, at risk of developing severe disease. A major contributing factor to continued malaria-associated mortality in the United States is delay in initiation of appropriate treatment (Newman 2004). In the five-year period between 1999-2004, there were 41 deaths from severe malaria in the United States (RD Newman, unpublished).

Based on surveillance data, an estimated 250 cases of complicated malaria requiring parenteral treatment occur every year in the US.

2.3 Diagnosis and treatment of severe malaria in the United States

A provisional diagnosis of severe malaria can be made in a patient who presents any of the features cited in Table 1, and who has malaria parasites demonstrated on microscopic examination of a blood smear. In most cases the parasite will be identified as *P. falciparum*. In some cases the parasites will be identified as *P. vivax*, *P. ovale*, or *P. malariae*, or a combination of the four species; or the microscopic examination may detect malaria parasites without being able to identify them specifically as being *P. falciparum* (diagnosis: *Plasmodium*, species undetermined). Because microscopic diagnosis is not always accurate (especially in the US, where laboratory personnel are not always familiar with malaria), a patient with the features of severe malaria (Table 1) and malaria parasites of any species should be treated as if having *P.*
*falciparum*, the species responsible for practically all cases of severe malaria. Treatment for *P. falciparum* will be effective against the blood stage of all four malaria species.

In some patients suspected of having severe malaria based on travel history, clinical findings, and exclusion of other causes of illness, a reliable microscopic diagnosis cannot be secured in a timely manner due to lack of laboratory facilities or trained personnel. Such patients can justifiably be treated presumptively for severe malaria, because the risk of death due to untreated severe malaria outweighs the risk of fatal adverse events caused by a presumptive (and possibly unnecessary) treatment.

Patients with severe malaria in the US should be treated with IV administration of a rapidly acting antimalarial drug (previously quinidine, now IV artesunate) (www.cdc.gov/malaria; hereafter will be referred as CDC malaria website 2019). Parenteral treatment aims to rapidly reach parasiticidal blood levels of the antimalarial drug, thus lowering the level of parasitemia and reversing end organ dysfunction and hemolysis. Although parenteral treatment is life-saving, because of its rapid action it often fails to eliminate all parasites; therefore, adjunct therapy is needed. Treatment with a follow-on, different drug ensures curative treatment through complete elimination of all remaining malaria parasites and includes atovaquone-proguanil, doxycycline, clindamycin, or if these drugs are not available, mefloquine (CDC malaria website 2019).

In addition, general supportive care should be given which may include infusion of intravenous fluids; correction of metabolic disturbance such as hypoglycemia or acidosis; blood transfusions; assisted ventilation; vasopressors; and renal dialysis (WHO 2015; CDC malaria website 2019).

Response to therapy should be assessed by clinical observations and measurements of laboratory parameters such as serial blood smears. The goals for treatment should be decrease in parasitemia and eventual parasitemia clearance.

In addition to patients with severe malaria, patients who are unable to ingest drugs orally due to nausea and vomiting (a frequent complication of malaria) should also receive parenteral therapy.

### 3.0 QUINIDINE

Quinine, a quinolinemethanol that is a component of the bark of cinchona trees, is the oldest known antimalarial drug and remains a key component in the treatment of severe malaria. Parenteral quinine is not commercially available in the United States, where by default severe malaria has historically been treated since 1991 with the D-isomer of quinine: quinidine (CDC 1991). The sole drug manufacturer of quinidine ceased production in 2017 and quinidine is no longer available for use in the US as of March 31, 2019.

### 4.0 ARTESTUNATE

Artesunate is an artemisinin derivative with excellent safety and efficacy data for the treatment of severe malaria. The WHO Guidelines for Treatment of Malaria (2015) recommend artemisinin derivatives as an essential component in the treatment of malaria (including severe malaria) worldwide (WHO 2015). While artemisinin derivatives have wide global availability and clinical usage, they have not yet been approved by the FDA for use in the United States.
WRAIR-manufactured IV artesunate is available for use under this CDC-sponsored IND 76,725/CDC IRB Protocol # 5032 for the treatment of severe malaria in the US; however, due to limited remaining stock of the WRAIR-manufactured product and anticipated increase in demand for IV artesunate due to quinidine unavailability, CDC will also provide IV artesunate manufactured by Guilin Pharmaceutical under CDC-sponsored IND 76,725/CDC IRB Protocol # 7171 for the treatment of severe malaria.

4.1 Artemisinin and its derivatives
Artemisinin is extracted from the “qinghaosu” or sweet wormwood plant (Artemisia annua L.) which has been part of traditional Chinese herbal medicine for centuries. Artemisinin was rediscovered and isolated in 1972 by Chinese scientists seeking new treatments for drug-resistant malaria, and was first reported in the medical literature in 1979. It is a sesquiterpene lactone with an internal peroxide linkage (Klayman 1985). The mechanism of antimalarial action of artemisinin has been hypothesized to involve an iron-mediated cleavage of the endoperoxide bridge, which produces oxygen radicals, which then react with nearby molecules, interfering with parasite function (Meshnick 1994). Various derivatives of artemisinin differ by the substituent at position #10. They include dihydroartemisinin, artemether, arteether, and artesunate. Artesunate is the hemisuccinate of the ester of dihydroartemisinin. It is water based, and rapidly biotransforms to its active metabolite, dihydroartemisinin, which has a short half-life of approximately 1 hour. Artemisinin derivatives have been used for more than two decades and are now a key component of treatment of malaria worldwide. They are available in formulations that allow administration by different routes (oral, parenteral, rectal). WHO supports their use as first-line antimalarial drugs, in combination with other antimalarial agents, in most malaria-endemic areas of the world. Such artemisinin-based combination therapies (ACT) aim to treat drug-resistant *P. falciparum* malaria rapidly and successfully, while at the same time slowing the emergence of resistance to artemisinin (WHO 2006).

![Artemisinin](image1)

![Artesunate](image2)

4.2 Artesunate: Efficacy
Experimental studies have demonstrated the efficacy of artesunate against malaria parasites cultured *in vitro*, and against malaria parasites in experimental animal models (rodent and non-human primates).

Artesunate has been used extensively to treat malaria for more than two decades outside the US.
Given intravenously, it has been highly effective, and has the advantage of a reliable and rapid pharmacokinetic profile. Studies on the treatment of severe malaria have been conducted in China, India, Thailand, Burma, Vietnam, Brazil, Ghana, Sudan, Gabon, and Malawi. These studies have utilized artesunate intravenously, intramuscularly, and rectally, alone and in combination with other drugs. Trials up to 1999 were summarized in the Cochrane Review Series (McIntosh and Olliaro, 2000). For the purposes of this protocol, only trials that employed intravenous artesunate for treatment of severe malaria are summarized below.

A study of 79 Vietnamese adults compared IV artesunate plus mefloquine, artemisinin suppositories plus mefloquine, and IV quinine. It demonstrated that IV artesunate cleared parasitemia and fever significantly faster than IV quinine, but no significant differences were found in duration of coma or mortality (Hien, 1992). Earlier unpublished studies (TK Anh, 1989) comparing artesunate to IV quinine in 41 Vietnamese adults, and follow-up unpublished studies by the same author (TK Anh) in 190 Vietnamese adults from 1992 to 1995 showed statistically significant differences in mortality favoring artesunate. A study in Myanmar among 141 Burmese adults with cerebral malaria showed significantly less mortality in the artemisinin-derivative arms (which included an arm with IV artesunate plus mefloquine) when compared with the IV quinine plus tetracycline arm (Win 1992).

A randomized, open-label trial compared IV artesunate and IV quinine in 113 adults with severe malaria in two centers in Thailand (Newton 2003). Mortality was 12% in the artesunate arm and 22% in the quinine arm (relative risk 0.53; p=0.22), suggesting that artesunate is at least as effective as quinine. Importantly, parasite clearance times were shorter and fewer patients developed hypoglycemia on artesunate therapy.

The largest and most definitive trials on the efficacy of artesunate were two multicenter, open-label randomized control trials implemented by the South East Asian Quinine Artesunate Malaria Trial (SEAQUAMAT) group and the African Quinine Artesunate Malaria Trial (AQUAMAT) group. The SEQUAMAT trial enrolled 1,461 patients with severe malaria in Bangladesh, India, Indonesia and Myanmar (SEAQUAMAT 2005). The trial was stopped early as researchers witnessed a significant reduction in mortality in the artesunate arm (15%) compared to the quinine arm (22%) with a relative risk of 0.69 (95% CI 0.54-0.83). The number of patients needed to receive treatment with artesunate to save one life, in comparison to patients treated with quinine, ranged from 11.1 to 20.2, depending on the countries. Artesunate was well tolerated while quinine was significantly associated with hypoglycemia. The AQUAMAT trial enrolled 5425 children in 11 African countries (AQUAMAT 2010). Mortality among those given artesunate (8.5%) was significantly lower than those given quinine (10.9%) with an odds ratio (adjusted for study site) of 0.75 (95% CI 0.63-0.90) and a relative reduction in mortality of 22.5% (95% CI 8.1-36.9; p=0.0022). There were no serious adverse events associated with artesunate, while quinine was associated with post-treatment hypoglycemia. The authors in both studies recommended that artesunate become the treatment of choice for severe *P. falciparum* malaria.

4.3 Artesunate: Toxicity

Clinical and animal studies suggest that artemisinin derivatives are much less toxic than the quinolines, the group that includes quinine and quinidine (Price 2000). While formal human toxicity studies on artesunate or the artemisinins in general are few, substantial clinical evidence and surveillance in Thailand all suggest that this drug class is relatively well-tolerated in adults and children.

4.3.1 Preclinical studies

Animal preclinical data suggest that the most common side effects of artemisinin derivatives might be reversible reticulocytopenia and mild hemolysis, of unknown mechanism (RS Miller, WRAIR, 2004 unpublished data). Neutropenia and diarrhea were seen in primates, but not in dogs. At high doses in non-human primates (>32 mg/kg), transient ataxia and hypersalivation have been observed. Toxicity studies of IV artesunate given for 14 days to beagle dogs detected no adverse effects except for a decrease in red blood cell parameters, including reticulocytes. Toxicity studies of beagle dogs given escalating doses of IV artesunate detected no cardiovascular or respiratory adverse effects. Toxicity studies in experimental animals (including rodents, monkeys, and dogs) demonstrated neurotoxic effects affecting mostly the brain stem (Miller and Blanchard, 2003). Such neurotoxicity has not been found in humans, which suggests that their occurrence in experimental animals were due to the high doses administered or the formulation used (Gordi and Lepist 2004).

The most important concern about this drug class has been the neurotoxicity reported in animals with the long-acting intramuscular oil-based artemisinins, such as arthemeter and arteether (Brewer 1998, Gordi and Lepist 2004). All the artemisinins, including artesunate are metabolized to dihydroartemisinin. Most experiments on artemisinins contain too many confounding variables to definitively determine the cause and mechanism of neurotoxicity, particularly since severe malaria may itself cause decreased neurologic function. Li et al (2002) concluded from studies with rats that prolonged drug exposure at low levels was related to a greater likelihood of severe neurotoxicity of artemisinin derivatives.

4.3.2 Human data

Artemisinin derivatives appear to be safe and have been used to treat several millions of cases of malaria without reported serious adverse events. Price (1999) combined findings from studies conducted in western Thailand during which 3,276 patients were treated orally with artesunate, of whom 2,646 also received mefloquine; 386 were treated with artemether, of whom 180 also received mefloquine; and 1,303 were treated with mefloquine alone. Symptomatic side effects in the pooled group of patients treated with artesunate or artemether monotherapy ranged from 34% (anorexia on Day 1-2), to 15-16% (dizziness-nausea on Day 1-2), to 1% (diarrhea on Day 1-2), and were generally less than the incidence of side effects in the mefloquine monotherapy group (54%, 54%-46%, and 3%, respectively). There was no evidence of neurotoxicity, cardiotoxicity, or allergic reactions attributable to the artemisinin derivatives. Adverse events (AEs) were noted in 17 patients, all of whom had received mefloquine either as monotherapy (2), in combination with artesunate (13) or with artemether (2). No AEs were noted in patients who had received artesunate monotherapy. The AEs consisted of urticaria, hemoglobinuria, seizures, neuropsychiatric reactions, and reversible neurologic changes, and could have resulted from malaria, mefloquine, or the artemisinin-based drugs.
Severe allergic reactions have been reported in case reports. Two out of 17,000 patients treated with artemisinin derivatives in Thailand developed pruritus and urticarial rashes, and dyspnea following oral artesunate (Leonardi 2001). Among 59 patients with severe malaria treated with IV artesunate in western Thailand, one patient developed an urticarial rash (Newton 2003).

4.3.3 Particulates in artesunate produced for clinical use
Small amounts of dihydroartemisinin may be present as particulates in the 10 to 25 micron range in the currently available clinical lot of artesunate produced for clinical use. The U.S. Pharmacopeia (USP) has established acceptable levels of particulates present at the ≥ 10 micron range. USP <788> sets these limits of acceptability for particle counts for vials less than 25 mL at less than 6000 particles/vial for the ≥ 10 micron range. Although all tests for particulates to date have been within the acceptable range, on January 18, 2008, CDC received particulate results that were in the upper range of the acceptable limits. All currently available laboratory evidence to date suggests that these particles are dihydroartemisinin, the active metabolite of artesunate which is less soluble in water than artesunate. When this product is administered through a 0.8 micron hydrophilic polyethersulfone filter, particulate counts are reduced to an essentially particulate free solution. While the Artesunate Integrated Product team at Walter Reed believes the presence of these particles do not necessarily pose a risk to patients receiving the product, use of the filter negates the possibility of effect without influencing the efficacy of the product. Thus, CDC is now recommending that artesunate should be administered using an in-line 0.8 micron hydrophilic polyethersulfone filter.

4.3.4 Delayed hemolytic anemia after treatment for severe malaria with artesunate
Between 2010 and 2012, 19 instances of delayed hemolytic anemia have been reported in the published literature following treatment of severe malaria with artesunate in other non-endemic countries (Kano 2010; Zoller, Junghanss et al. 2011; Caramello, Balbiano et al. 2012; Kreeftmeijer-Vegter, van Genderen et al. 2012; Rolling, Schmiedel et al. 2012). As of September 2012, CDC recommended that persons treated for severe malaria with artesunate be evaluated for up to 4 weeks after that treatment for evidence of hemolytic anemia. Two cases of delayed hemolytic anemia have been identified in the United States after the use of WRAIR-supplied artesunate for the treatment of severe malaria under this IND protocol. Artesunate kills the intraerythrocytic malaria parasites which are then removed from the red blood cells by the spleen. The leading hypothesis for the occurrence of delayed hemolytic anemia is that the previously infected red blood cells have a decreased life span compared to red blood cells that were never infected. So rather than being lysed by the parasites at the time of the severe malaria episode, the red blood cells are cleared by the spleen about 7-14 days after the treatment with artesunate in a self-limited hemolytic event. Persons with higher parasitemias seem to have a higher likelihood of delayed hemolytic anemia after treatment with artesunate. Depending on the amount of hemolysis, transfusion may be needed. Any instances of hemolytic anemia after treatment with artesunate should be reported immediately to the principal investigator, Dr. Kathrine Tan at (404)718-4701.
4.4. Artesunate and pregnancy

The information below is referenced from IND 64, 769, “The Summary of studies on the adverse effects of AS on pregnancy of humans and animals: studies reported in literature and conducted in house” which summarizes the literature and current studies at WRAIR:

- Artesunate causes fetal toxicity in rats and rabbits resulting in fetal resorption and abortion, as well as a low incidence of cardiac malformations and skeletal defects.

- Studies in rats at WRAIR indicate that artesunate crosses the placental barrier and accumulates in the placenta and fetus, which may explain the observed fetal toxicity.

- From 1999 to 2006, a total of 2,045 pregnant women participating in clinical trials in Thailand, the Gambia, and Sudan were treated with artesunate alone or in combination with other antimalarial drugs (such as quinine, mefloquine, atovaquone-proguanil and sulfadoxine-pyrimethamine). Most of these patients were in the second and third trimesters of pregnancy. The investigations found no significant differences from community rates in birth weight, duration of gestation, placenta weights, or congenital abnormality rates in newborns at delivery or in growth and developmental parameters of infants monitored for one year.

McGready (2001) assessed artesunate safety in western Thailand, where 461 pregnant women were treated with artemisin derivatives (predominantly artesunate) with no evidence of adverse effects. In 414 women with known pregnancy outcomes, the rates of abortion (4.8%), stillbirth (1.8%), congenital abnormalities (0.8%), and low birth weight (19.0%) did not differ significantly from rates found in the community. The vast majority of study participants were in their second or third trimesters of pregnancy. In 44 women who received artemisinin derivatives during the first trimester of pregnancy, the abortion rate was not significantly different from the community rate.

Moore (2016) conducted an observational study of 55,636 pregnancies on the Thai-Burma border between 1994 and 2013, assessing the effects of instances of malaria during the first trimester as well as the effects of different malaria medicines on rates of miscarriage and major congenital malformations. There was no difference in those rates for women treated with artemisinins compared to those treated with quinine. The conclusion from this article is that artemisinins including artesunate appear to be safe for use during the 1st trimester of pregnancy.

Thus, while animal studies indicate that artesunate can have harmful effects on pregnancy, no such effects have been documented in humans. Ongoing studies continue to demonstrate the safety of artemisinins during pregnancy. Considering that severe malaria represents a substantial risk for pregnant women and their fetuses, WHO recommends that pregnant women with severe malaria be treated with artesunate or quinine in the first trimester, and with artesunate preferentially to quinine in the second and third trimesters (WHO 2006).
5.0 ARTESUNATE: PRODUCT SOURCE AND DESCRIPTION

5.1 Product
The investigational product to be used in this protocol is the WRAIR’s formulation of IV artesunate, WR256283. The product will be provided as a sterile dry-filled powder with a diluent for reconstitution, phosphate buffer. Once reconstituted, the drug should be administered through a 0.8 micron polyethersulfone in-line filter as a precautionary safety measure regarding any potential precipitation of the product.

The bulk drug was purchased from Knoll Pharmaceuticals, and manufactured by SRI International, Menlo Park, CA, US, Batch # 14462-16 (Bottle # BR 29487). It was produced in September – October 2004. Scheduled stability and degradation studies will be conducted at regular interval to ensure the drug’s chemical stability. Only drug products with a current certificate of analysis will be used. No expired drug will be used. The drug label will also contain the following: Store at 2 – 10 degrees Celsius. CAUTION: INVESTIGATIONAL NEW DRUG LIMITED BY FEDERAL LAW TO INVESTIGATIONAL USE.

The phosphate buffer (USP), also manufactured by SRI International, Menlo Park, CA, US, Lot #: 090403-B, will be used as diluent for artesunate in this trial. The phosphate buffer will be stored at 2° to 30° Celsius.

IV Artesunate (WR256283) will be supplied with a certificate of analysis and a statement of the expiration or re-test date. CDC will provide the investigational product that has been packaged to prevent contamination or deterioration during transport and storage.

5.2 Current WRAIR trials with product
The product is currently being used by WRAIR in several ongoing clinical trials under IND 64,769. A single-dose safety studies demonstrated the virtual lack of any measurable side effects in doses approaching currently up to 8 mg/kg, nearly four times the recommended dose. Minor, extremely transient side effects consisted of minor lightheadedness in up to 40% of the participants at the time of infusion and an alteration of taste (metallic taste) in up to 50% of the participants (prior to breaking the code).

An ongoing study using repeated dosing aims to assure that there is no cumulative toxicity, which is not predicted by available information on the pharmacokinetics of artesunate and its metabolites, or by several published observational studies of cumulative toxicity.

In a safety and efficacy study, Kenyan adults with non-complicated P. falciparum malaria were treated with this cGMP IV artesunate at the same drug regimen as proposed in this CDC program. No major adverse events have been noted in 30 subjects. The pharmacokinetics and efficacy of the product were comparable to those of previously used (non-ICH cGMP) artesunate preparations.

Currently scheduled trials include: dose optimization trials in uncomplicated malaria in adults in both Kenya and Thailand; safety and efficacy trial in children with severe malaria in Gabon and Malawi; safety, efficacy, and population pharmacokinetics trial in children with uncomplicated
malaria in Kenya. The close working relationship of CDC and WRAIR will assure that findings from these trials will be rapidly communicated to improve this CDC program if appropriate. The results of the scheduled trials will also be communicated to the IRB in a timely manner.

6.0 OBJECTIVE

The primary purpose of this program is to make available intravenous artesunate for treatment of severe malaria in US hospitals because parenteral quinidine is no longer available. CDC should be notified of adverse events associated with the administration of artesunate for reporting in accordance with 21 CFR 312.32.

7.0 TREATMENT DESIGN

7.1 Inclusion Criteria/Eligibility

In order to be eligible for IV artesunate, a patient must meet the following criteria:

a. Malaria confirmed by microscopy. It is expected that the great majority of the eligible cases will diagnosed as *Plasmodium falciparum*. Patients with other microscopic diagnoses of malaria (*Plasmodium* of undetermined species, or species other than *falciparum*) will also be eligible, taking into account the unfamiliarity of some US laboratories with malaria diagnosis and the importance of timely treatment of severe malaria. In exceptional cases, microscopic diagnosis might be waived, e.g., a patient with strong clinical suspicion of severe malaria, for whom a timely, reliable microscopic diagnosis is not available (current CDC guidelines advise that in such cases, parenteral antimalarial treatment is justified).

b. Parenteral treatment required due to one or more of the following reasons (1, 2, or 3):
   1. Unable to take oral medications
   2. High density parasitemia (>5%)
   3. Severe malaria based on:
      i. Impaired consciousness
      ii. Seizures
      iii. Circulatory collapse/shock
      iv. Pulmonary edema or acute respiratory distress syndrome (ARDS)
      v. Acidosis
      vi. Acute renal failure
      vii. Abnormal bleeding or disseminated intravascular coagulation (DIC)
      viii. Jaundice
      ix. Severe anemia (Hb < 7 g/dL)

7.2 Exclusion Criteria

a. Known allergy to artesunate
7.3 Special considerations: Pregnant Women

For pregnant women, especially in the first trimester of pregnancy: the lack of data regarding potential artesunate teratogenicity must be weighed against the risks of severe malaria in the context of quinidine unavailability or unsuitability. Ultimately, malaria is life threatening for both the pregnant woman and the fetus, and artesunate should not be withheld if quinidine is unavailable, contraindicated, ineffective, and/or not tolerated.

7.4 Procedures

a. Malaria Branch medical epidemiologists who take CDC Malaria Hotline clinical calls from physicians will determine eligibility using the “Eligibility for IV Artesunate” form (Appendix I).

b. If the patient meets eligibility criteria and the attending physicians agree, CDC Malaria Branch staff will fax and/or email the required consent form (Appendix V) and drug administration protocol (Appendices II, III) to the physician or other health care provider.

c. CDC Malaria Branch staff will initiate the procedure for release of IV artesunate from the CDC Drug Service or Quarantine Station to the appropriate treatment facility (Appendix IV).

d. Artesunate will be released from CDC Drug Service or Quarantine Station to the treatment facility as rapidly as possible (ground courier or air), preferably within 2 hours.

e. Artesunate will be administered at the health facility, with a treating physician serving as a site investigator. Consultation with CDC medical epidemiologists as needed.

f. All Serious Adverse Events (SAE) associated with IV AS treatment must be reported to CDC within 24 hours by telephone. The Adverse Event Report form (Appendix III) should be completed and sent to CDC within 10 calendar days by fax, email, or regular mail. See Appendix III for appropriate contact information.

8.0 ADMINISTRATION OF ARTESUNATE AND FOLLOW-ON TREATMENT

8.1 Artesunate

The investigational product IV artesunate (WR256283) will be provided as a sterile dry-filled powder and will be prepared for administration by reconstitution in the sodium phosphate buffer prior to infusion.

Reconstitution and administration of IV artesunate:

The formulation of artesunate consists of two parts. Part A is a vial filled with base artesunate, the active component; Part B (diluent) is a vial filled with phosphate solution used to dissolve the artesunate in Part A just prior to administration. Specifically, 11 ml of diluent will be withdrawn from the diluent vial (Part B) and injected into the artesunate vial (110 mg of artesunate) (Part A). This mixture will be gently swirled for 5 to 6 minutes (resulting in a concentration of 10 mg/ml) and will be administered within 1 hour. The reconstituted drug will be injected intravenously (through
an established intravenous line or needle) pushed over 1-2 minutes through a 0.8 micron hydrophilic polyethersulfone filter.

**Schedule and dosage of IV artesunate:**
IV artesunate should be administered intravenously slowly over 1-2 minutes at 0 hour, 12 hour, 24 hour, and 48 hour for a total of 4 doses. The following weight-based dosing should be used to calculate the correct dose for administration:

- **Adults and children ≥ 20 kg:** 2.4 mg/kg at 0 hour, 12 hours, and 24 hours, and 48 hours
- **Children < 20 kg:** 3.0 mg/kg at 0 hour, 12 hours, and 24 hours, and 48 hours

The dose in persons > 20 kg is the same dosage as used in the SEAQUAMAT trial. The slightly higher dosage in children < 20 kg is in line with the WHO-recommended dosage based on pharmacokinetic modeling demonstrating a larger volume of distribution in children of that size. (WHO 2015)

**8.2 Follow-on treatment**
Please note that the follow-on treatment is not part of this program and will not be provided by CDC.

In parts of the world where IV artesunate is used, it is typically followed by an oral medication once the patient is able to tolerate medications by mouth. Although artesunate is a life-saving drug, because of its rapid action, it often fails to eliminate all parasites; therefore necessitating adjunct therapy. This is similar to the current standard of care regimens in the United States in which the rapidly acting drug such as quinine and quinidine is always coupled with a follow-on drug such as doxycycline or clindamycin. Treatment with a follow-on, different drug ensures curative treatment through complete elimination of all remaining malaria parasites. Because IV artesunate has a short half-life (less than 2 hours), potential drug-drug interactions should not be an issue. The treating physicians should make sure to use an appropriate follow-on drug to complete the treatment of malaria. The choice of which follow-on drug to use is at the discretion of the treating physician. The follow-on oral drug should be initiated on the last day of artesunate treatment, at least 4 hours after the IV dose of artesunate. The treating physicians should choose to use one of the drugs recommended by CDC against chloroquine-resistant *P. falciparum* (CDC malaria website, 2006), by order of preference:

**8.2.1 Atovaquone-proguanil (AP, Malarone)** is the follow-on drug of first choice, and will be given to most patients.

Atovaquone-proguanil was also the oral follow-on drug used in previous clinical studies of IV artesunate in Kenya. AP has been studied in combination with oral artesunate for treatment of uncomplicated malaria and no evidence of cardiotoxicity was found (Gupta 2005).

Atovaquone-proguanil is available in two strengths, adult (250 mg atovaquone/100 mg proguanil) and pediatric (62.5 mg atovaquone/25 mg proguanil).
Adults will receive AP 1 g/400 mg (four adult tabs) every day for 3 consecutive days.

Children will receive AP doses based upon body weight as indicated below.

- 5 – 8 kg: 2 peds tabs po every day for 3 consecutive days
- 9 – 10 kg: 3 peds tabs po every day for 3 consecutive days
- 11 – 20 kg: 1 adult tab po every day for 3 consecutive days
- 21 – 30 kg: 2 adult tabs po every day for 3 consecutive days
- 31 – 40 kg: 3 adult tabs po every day for 3 consecutive days
- > 40 kg: 4 adult tabs po every day for 3 consecutive days

Note: AP is not recommended for infants under 5 kg.

8.2.2. Doxycycline (or clindamycin for children under 8 years and pregnant women) will be the follow-on drug for patient who cannot take AP. Adult dosage of doxycycline: 100 mg po bid for 7 days; pediatric dosage (children 8 years or older) 4 mg/kg/day divided bid for 7 days. Children under 8 years of age or pregnant women should receive instead clindamycin 20 mg base/kg/day divided tid for 7 days.

8.2.3 Mefloquine, although a highly efficacious antimalarial, will be the follow-on drug of last choice because of the relatively high rate of adverse drug reactions in persons who receive treatment doses of mefloquine. Adult dosage: initial dose of 750 mg salt po followed by 500 mg salt 6-12 hours after initial dose; pediatric dosage: 15 mg salt/kg po as initial dose, followed by 10 mg salt/kg po given 6-12 hours after initial dose.

8.3 Patients still not tolerating oral medications after 3 days of IV artesunate:
The vast majority of patients will have recovered after 3 days of treatment with IV artesunate. For those patients who still cannot tolerate oral medications, several treatment options are available, depending on the patient’s clinical and parasitological status. The most suitable course of treatment should be selected by the attending clinicians in consultation with CDC. Potential options include:

1. Continue IV artesunate, not to exceed a total course of 7 days
2. Switch to treatment with IV doxycycline (7 days) or IV clindamycin (7 days).

(These regimens are described more in detail on the CDC website https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html).

As soon as the patient can tolerate oral medications, switch to an appropriate oral follow-on treatment.

9.0 SUPPORTIVE CARE AND FOLLOW-UP
Patients should be treated in intensive care units, and should receive appropriate supportive treatment required by their clinical status (e.g., fluid administration, transfusions, assisted ventilation, vasopressors, etc.).
A thin blood smear should be prepared and read by an experienced microscopist to determine baseline parasite density, expressed as a percent of red blood cells infected. Blood smears should be repeated every 12 - 24 hours until at least two consecutive blood smears are negative, and also at the end of treatment.

Any adverse events (AE) potentially associated with the administration of artesunate should be treated appropriately.

10.0 SAFETY DATA COLLECTION AND REPORTING

Attending or treating physicians are responsible for the real-time collection and evaluation of safety data. The occurrence and outcome of all AEs meeting the AE definition below should be documented to the extent possible, including relevant clinical data and concomitant medication for patients who experience an AE during and up to 28 days post completion of IV artesunate treatment course. All AEs meeting reporting criteria (see definitions below) should be documented on the Adverse Event Reporting Form (Appendix III), and faxed, emailed, or mailed to the Principal Investigators within 10 days of AE occurrence. All SAEs should be notified to the Malaria Branch by telephone within 24 hours of occurrence and followed up with a completed Adverse Events Report Form (Appendix III) which should be faxed, emailed, or mailed to the Principal Investigators within 10 days of SAE occurrence. Please be informed that cases of delayed hemolysis occurring up to 28 days after IV artesunate treatment should be reported as an AE. Appendix III including the Supplemental Form for Delayed Hemolysis should be completed and submitted to CDC.

The Principal Investigator and Sub-investigators at the CDC Malaria Branch may request additional information from attending physicians for their review of SAEs.

Definitions of Adverse Events (AEs)

An ADVERSE EVENT (AE) is any untoward medical occurrence associated with the use of a drug/biologic in humans, whether or not considered related to artesunate. It can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of artesunate, without any judgment about causality, that was not present prior to initiation of IV artesunate treatment. Any medical condition or laboratory abnormality that was present prior to IV artesunate treatment should be considered as a baseline condition and not an AE. However, if an existing medical condition deteriorates at any time during and through 28 days post completion of IV artesunate treatment, it should be recorded as an AE. Complete Appendix III for all AEs.

A SUSPECTED ADVERSE REACTION is any AE for which there is a reasonable possibility that artesunate caused the adverse event. It is a subset of all AEs for which there is a reasonable possibility that artesunate caused the event. “Reasonable possibility” means there is evidence to suggest a causal relationship between artesunate and the AE. “Suspected adverse reaction” implies a lesser degree of certainty about causality than “adverse reaction.” An ADVERSE REACTION is any AE caused by artesunate. Adverse reactions are a subset of all suspected adverse reactions for which there is a reason to conclude that artesunate caused the event.
UNEXPECTED: An AE is considered “unexpected” if it is not listed in this protocol or is not listed at the specificity or severity observed.

SERIOUS: An AE or suspected adverse reaction is considered “serious” if in the view of either the treating physician or CDC, it results in any of the following outcomes:

- death
- a life-threatening AE
- inpatient hospitalization or prolongation of existing hospitalization
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- a congenital anomaly/birth defect

NOTE: Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes listed in this definition.

LIFE-THREATENING: An AE or suspected adverse reaction is considered “life-threatening” if, in the view of either the treating physician or CDC, its occurrence places the patient at immediate risk of death. It does not include an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused a death.

**CDC Reporting Requirements to FDA and CDC IRB**

Upon receipt of reported AEs from treating physicians, CDC will review to determine any suspected adverse reactions that are both serious and unexpected. Any adverse events that are determined to be serious and unexpected will be reported to FDA within 15 calendar days. Per 21 CFR 312.32, a suspected adverse reaction is determined based on evidence to suggest a causal relationship between artesunate and the AE, such as:

a) A single occurrence of an event that is uncommon and known to be strongly associated with artesunate.

b) One or more occurrences of an event that is not commonly associated with artesunate, but is otherwise uncommon in patients who received artesunate for treatment.

c) Aggregate analysis of specific events observed in this treatment program that indicates those events occur more frequently in the patients treated with artesunate than in a concurrent or historical control group in which no artesunate treatment was given.

CDC will also report to FDA within 15 calendar days any clinically important increase in the rate of a serious suspected adverse reaction and any findings from clinical studies or animal studies or in vitro testing that suggest a significant risk in humans exposed to artesunate. Unexpected fatal or life-threatening suspected adverse reactions will be reported to FDA as soon as possible and no later than 7 calendar days after CDC’s initial receipt of the information. CDC will also report AEs and incidents to CDC IRB according to CDC IRB’s policy and procedures.
**AE Follow-Up**

All AEs should be followed to resolution to the extent possible and outcomes classified as recovered, sequelae, death, or lost-to-follow-up. Additional information may be requested by CDC to complete AE follow-up.

**11.0 DATA COLLECTION, HANDLING, AND RECORDKEEPING**

Treating physicians are responsible for data collection, handling, and recordkeeping pertaining to patients receiving IV artesunate under their care. Treating physicians should complete the Demographics forms and the Treatment Plan forms (Appendix I and II) and submit them to CDC. Adverse Event forms (Appendix III) should be completed and returned to CDC if the patient experiences an AE. To the extent practicable, safety information should be collected on cases experiencing AEs, during and up to 28 days after IV artesunate treatment and reported to CDC as appropriate.

CDC Drug Service will document all releases through its secure database. CDC Malaria Branch will manage data collection and submitted patient data including reports of AE will be kept in a secure database. All data from AE cases will be included in the evaluation of safety.

**12.0 Program Modifications**

Changes or modification to the existing protocol should not be implemented without a formal amendment to the protocol except to eliminate an immediate risk to patients. If protocol amendments necessitate a change in the informed consent form (ICF) it may be necessary for a participant currently receiving treatment under the protocol to be informed about the revision and asked to sign the revised ICF. A copy of the revised, signed (with date) ICF should be given to the participant and all original versions of the ICF retained as part of the participant’s permanent record. Copies of signed ICF will be retained at CDC.

**13.0 PROGRAM RESPONSIBILITIES**

**13.1 Principal Investigators**

The Principal Investigator is responsible for coordinating the activities and implementation of the protocol with the Malaria Branch staff and the CDC Drug Service as well as monitoring the safety of participants receiving IV artesunate.

**13.2 CDC Malaria Branch Medical Officers/Epidemiologists**

CDC Malaria Branch Medical Officers/Epidemiologists will respond to clinical calls and will evaluate all severe malaria cases to determine eligibility and, if necessary, initiate the protocol. The Malaria Branch Medical Officers/Epidemiologists will be responsible for initiating drug delivery and conducting follow-up phone calls.

**13.3 Clinicians in Healthcare Facilities**

Clinicians are responsible for determining whether the patient fulfills criteria for administration of artesunate; contacting CDC; administering the drugs as described in the protocol; and
reporting to CDC any AEs recorded during the program—whether or not considered to be related to the administration of artesunate.

14.0 ETHICAL, Legal, and Administrative Requirements

14.1 Current Good Clinical Practice (cGCP)

The procedures set forth in this program are designed to ensure that the Sponsor and all program personnel abide by the Code of Federal Regulations (in particular, 21 CFR, Parts 56, 312, 314, and 600) and ICH Guidelines for GCP. By signing Form FDA 1572 (Investigator’s Agreement Form), each treating physician is agreeing to abide by these regulations and guidelines.

14.2 Informed Consent

Written informed consent, either from each participant or the participant’s legal guardian, in compliance with 21 CFR 50, must be obtained before any program-related procedures are initiated. The ICF must be dated, witnessed, and retained by the investigator as part of the program records at the medical facility administering the product. Each participant will receive a copy of the signed ICF and any revised ICF. If the signed form is lost, the participant will be required to sign and date a new ICF before receiving subsequent treatment. Because artesunate will be used for a potentially life-threatening illness, the ultimate responsibility for decision making for this product for all minors should be the parent or guardian.

Informed consent includes the principle that it is critical that the individual be informed about the potential risks and benefits of participating in this program. This information will allow individuals to make a personal risk-versus-benefit decision and understand the following general principles:

1. Participation in this program is entirely voluntary.
2. Participants may withdraw from participation in this program at any time without penalty or loss of benefits to which they are otherwise entitled.
3. Refusal to participate in this program involves no penalty.
4. The individual is free to ask any questions that will allow him/her to understand the nature of this program.

If a patient is unable to respond and make wishes known about artesunate treatment, and no next-of-kin or legal representative is available, and the patient’s illness is life-threatening, per 21 CFR 50.23 “Exception from General Requirements”, informed consent may be deemed not feasible and the treating physician can make the determination to administer artesunate. Per 21 CFR 50.23, the patient’s treating physician, acting as site investigator, and a physician who is not otherwise participating in this expanded access IND treatment program, will document the following on the consent form and will return a copy of the consent form to CDC.

1. Patient is confronted by a life-threatening situation necessitating the use of artesunate.
2. Informed consent cannot be obtained from the patient because of an inability to communicate with, or obtain legally-effective consent from, the patient.
3. Time is not sufficient to obtain consent from the patient’s legal representative.
4. There is available no alternative method of approved or generally recognized therapy that provides an equal or greater likelihood of saving the life of the patient.

CDC will also report the above to CDC IRB as required and according to CDC IRB’s policy and procedures.

If immediate use of artemisinin is, in the treating physician’s opinion, required to preserve the life of the patient, and time is not sufficient to obtain the independent determination required above in advance of administering artemisinin to the patient, the determinations of the treating physician shall be made and, within 2 working days after the use of artemisinin, be reviewed and evaluated in writing by a physician who is not participating in this treatment protocol.

14.3 Risks
The risks to the patients include:

1. Accidental disclosure of private identifiable information
2. Risks inherent to the procedures needed for the diagnosis and treatment of severe malaria
3. Risks of AEs and SAEs, or lack of treatment effectiveness.

To minimize the risks of disclosure of private information, the patients’ records and identifiable databases will be kept under conditions of confidentiality routinely followed in hospitals. At CDC, the participants’ records will be kept in locked, secure storage areas at the Drug Service and the Malaria Branch. To minimize the risks inherent to diagnostic and treatment procedures and the risks of AE and SAEs, all medical personnel and CDC investigators will exercise due care in the management of the patients. These risks are justifiable in relation to the anticipated benefits to the patient, namely treatment of a potentially fatal disease with an effective, rapidly-acting antimalarial drug.

14.4 Inclusion of children
Any person with severe malaria in the US requires appropriate IV antimalarial treatment, and IV artemisinin is the only option in the US. Therefore, those treated with IV artemisinin under this IND may include those in vulnerable populations. This protocol is greater than minimal risk, but presents the prospect of direct benefit to patients. The risk of adverse drug reaction is far outweighed by the benefit of being treated for severe malaria, a potentially fatal disease. The relation of the anticipated benefit to the risk is more favorable than that of other available treatments, as one of the eligibility criteria for this treatment is that other available treatments are not clinically appropriate.

In accordance with 21 CFR 50.55, permission will be sought from a parent or guardian. Minors who are legally able to give consent under local laws will not be considered children.
14.5 Privacy and Confidentiality

Participant identification number and date of birth will identify participants in a secure CDC database. Participants should be advised that they could be contacted by telephone or by mail at later dates for follow-up through their treating physician. This follow-up includes safety surveillance.

Representatives of the Sponsor, drug manufacturer, and the FDA are eligible to photocopy and review medical and program records related to this program as a part of their responsibility to protect human participants in this program.

No personal data will be used in any external communication or publication.

15.0 FINANCING AND INSURANCE

The CDC is funding this program. Should a participant be injured as a direct result of participating in this program, he/she will receive medical care for that injury. Should a participant require medical treatment, the costs for hospital and medical care will not be covered by the CDC and will need to be paid by the participant, the participant’s insurer, Medicare, or Medicaid. The participant should be informed that this does not constitute a waiver or release of legal rights. The investigators or designees should discuss this issue with the participant or legally authorized representative at the clinical site.

16.0 PUBLICATION POLICY

All data collected during the course of this program may be published in the open medical literature with the identity of the participants protected.
17.0 REFERENCES


19. Miller RS, Blanchard TW. Toxicology of subacute, 7-day dosing of candidate intravenous artemisinins in Rhesus monkeys. In Weina PJ, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences (USAMC-AFRIMS), Bangkok, Thailand: 41.


APPENDICES

APPENDIX I: DEMOGRAPHICS
APPENDIX II: TREATMENT PLAN
APPENDIX III: ADVERSE EVENT REPORT FORM
APPENDIX IV: LIST OF CDC QUARANTINE STATIONS
APPENDIX V: PARTICIPANT CONSENT / PARENTAL PERMISSION FORM
APPENDIX I

Participant ID: ☐ ☐ ☐ ☐ ☐

Study Inclusion

Date Informed Consent form signed (dd/mön/yyyy): __ __/__ __ __/ __ __ __ __

Determining eligibility:
A patient is eligible to receive intravenous (IV) artesunate treatment if at least one criterion is satisfied in EACH of sections A and B.

Section A: (Malaria diagnosis). One of the following criteria must be satisfied:
☐ Malaria confirmed by microscopy
☐ Strong clinical suspicion of severe malaria, but timely microscopic confirmation is not possible, and parenteral treatment with antimalarial drug is urgently needed.

Section B: (Need for IV treatment). At least one of the following criteria must be satisfied (Check all that apply):
☐ Unable to take oral medication
☐ Parasitemia > 5% (parasitemia:___________)
☐ Impaired consciousness
☐ Seizures
☐ Circulatory collapse/shock (vasopressors used: ☐ YES ☐ NO)
☐ Pulmonary edema or acute respiratory distress syndrome
☐ Acidosis
☐ Acute renal failure (BUN:_______ creatinine: ____________)
☐ Abnormal bleeding or disseminated intravascular coagulation (DIC)
☐ Jaundice (bilirubin: ______________)
☐ Severe anemia with hemoglobin under 7 gm/dL (hemoglobin: __________)  

DOES THE PATIENT MEET ELIGIBILITY CRITERIA? ☐ YES ☐ NO
(At least one criterion in each of the sections A and B)

*: Precautions concerning artesunate:
- Patients with known allergy to artesunate or other artemisinin derivatives should not receive artesunate
- For pregnant women, especially women in the first trimester of pregnancy: the lack of data regarding potential artesunate teratogenicity must be weighed against the risks of severe malaria in the context of quinine unavailability or unsuitability. Ultimately, malaria is life-threatening for both the pregnant woman and the fetus, and artesunate should not be withheld if quinidine is unavailable or unsuitable.

Date informed consent form signed (dd/mön/yyyy): __ __/__ __ __/ __ __ __ __
Participant ID: ☐ ☐ ☐ ☐ ☐

Demographics

1. Today’s date: ____________________________
2. CDC Epidemiologist: ____________________________
3. Station delivering artesunate ____________________________
4. Patient’s Name: ____________________________
5. Patient’s Medical Record Number: ____________________________
6. Patient’s Date of Birth__________________________
7. Patient’s Gender: ☐ Male ☐ Female
8. Is Patient of Hispanic or Latino ethnicity? ☐ Yes ☐ No
9. Check the primary race of the patient. If patient considers him/herself of more than one race, check ‘Other’ and specify the races:

| ☐ White | ☐ Asian |
| ☐ Black or African American | ☐ Native Hawaiian or Other Pacific Islander |
| ☐ American Indian or Alaska Native | ☐ Other, specify races: ____________________________ |
10. Is the patient pregnant: ☐ Yes ☐ No ☐ N/A
    If yes, how many weeks? ______________
11. Parasite species: ☐ Pf ☐ Pv ☐ Po ☐ Pm (Check all species that apply)
    ☐ Unknown ☐ Smear not performed ☐ Smear not read
12. Parasite density: ___________%
13. Admission laboratory results:

<table>
<thead>
<tr>
<th>Lab</th>
<th>Value</th>
<th>Unit</th>
<th>Date drawn (dd/mm/yyyy)</th>
<th>Time drawn (hh:mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>g/dL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Hematocrit</td>
<td>%</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Platelets</td>
<td>/uL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>White blood cells</td>
<td>/uL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Chloride</td>
<td>mEq/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>BUN</td>
<td>mg/dL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Creatinine</td>
<td>mg/dL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Glucose</td>
<td>mg/dL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Lactate dehydrogenase (LDH)</td>
<td>U/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>AST</td>
<td>U/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>ALT</td>
<td>U/L</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
<tr>
<td>Bilirubin, total</td>
<td>mg/dL</td>
<td></td>
<td><em><strong>/</strong></em>/_____</td>
<td><em><strong>:</strong></em></td>
</tr>
</tbody>
</table>

14. Physician’s Name ____________________________________________

15. Physician’s Phone  
   i. Office: ____________________________  
   ii. Pager: ____________________________  
   iii. Cellular: ________________________  

16. Hospital Name__________________________

17. Hospital Address ____________________________

                           ____________________________
                           Hospital Phone: ____________________________
APPENDIX II

Participant ID: □□□□□

- Determine patient’s dose of artesunate:

   **Adults and children > 20 kg:**
   - Artesunate 2.4 mg/kg at 0 hour, 12 hours, and 24 hours, and 48 hours

   **Children < 20 kg:**
   - Artesunate 3.0 mg/kg at 0 hour, 12 hours, and 24 hours, and 48 hours

- Reconstitute artesunate
  
The formulation of artesunate consists of two parts. Part A is a vial filled with base artesunate, the active component; Part B (diluent) is a vial filled with phosphate solution used to dissolve the artesunate in Part A just prior to administration.

  Specifically, 11 ml of diluent will be withdrawn from the diluent vial (Part B) and injected into the artesunate vial (110 mg of artesunate)(Part A). This mixture will be gently swirled for 5 to 6 minutes (resulting in a concentration of 10 mg/ml) and will be administered within 1 hour.

- Artesunate for injection
  - Manufactured by SRI International, Menlo Park, CA, US
  - Lot #: 090403-A, produced in September 2003

- Phosphate Buffer USP (diluent), 0.3 Molar, pH 8.1
  - Manufactured by SRI International, Menlo Park, CA US
  - Lot #: 090403-B, produced in September 2003

- Administer the reconstituted drug intravenously by injection into an established intravenous line or needle over 1-2 minutes through a 0.8 micron hydrophilic polyethersulfone filter.

- Watch patient for 30 minutes. Observe any development of allergic symptoms such as itching, redness, swelling, shortness of breath, chest pain, or watery eyes.

  If patient develops any allergic reaction manage symptoms accordingly and discontinue treatment.

- If the patient experiences any Serious Adverse Events (SAEs), report them to CDC within 24 hours by telephone.

- Complete the Adverse Events Report Form. If the patient experiences any Adverse Events regardless of potential relationship to artesunate, it must be reported within 10 days of the AE.

**Follow-on Oral Treatment**

The follow-on oral drug should be initiated on the last day of artesunate treatment, at least 4 hours after the IV dose of artesunate. Use ONE of the following, by decreasing order of preference:
Participant ID: □□□□□

1. **Atovaquone-proguanil (Malarone)** (first choice)

   Adults: Tabs of 250/100 mg: four tabs po daily for 3 consecutive days  
   Children: Tabs of 62.5/25 mg (peds tabs) or 250/100 mg (adult tabs) po at the following weight-based doses:
   - 5 – 8 kg: 2 peds tabs po daily for 3 consecutive days  
   - 9 – 10 kg: 3 peds tabs po daily for 3 consecutive days  
   - 11 – 20 kg: 1 adult tab po daily for 3 consecutive days  
   - 21 – 30 kg: 2 adult tabs po daily for 3 consecutive days  
   - 31 – 40 kg: 3 adult tabs po daily for 3 consecutive days  
   - > 40 kg: 4 adult tabs po daily for 3 consecutive days  

   **Note:** Atovaquone-proguanil is not recommended for infants under 5 kg.

2. **Doxycycline** (or clindamycin for children under 8 years or pregnant women) (second choice; for patients who cannot take atovaquone-proguanil)

   Adults (excluding pregnant women: 100 mg doxycycline po bid for 7 days  
   Children (8 years or older): 4 mg/kg/day doxycycline divided bid for 7 days  

   Children under 8 years or pregnant women: instead of doxycycline, administer clindamycin 20 mg base/kg/day divided tid for 7 days

3. **Mefloquine** (third choice, for patients who cannot take atovaquone-proguanil, doxycycline, and clindamycin)

   Adults: Initial dose of 750 mg salt po followed by 500 mg salt 6-12 hours after initial dose  
   Children: Initial dose of 15 mg salt/kg po followed by 10 mg salt/kg po given 6-12 hours after initial dose

**Patients still not tolerating oral medications after 3 days of IV artesunate:**

If, after 3 days of treatment with IV artesunate, the patient still cannot tolerate oral medications, several treatment options are available, depending on the patient’s clinical and parasitological status. The most suitable course of treatment should be selected by the attending clinicians in consultation with CDC. Potential options include:

1. Continue the IV artesunate, not to exceed a total course of 7 days  
2. Switch to treatment with IV doxycycline (7 days) or IV clindamycin (7 days).  
   *(these regimens are described more in detail on the CDC website https://www.cdc.gov/malaria/diagnosis_treatment/treatment.html)*

As soon as the patient can tolerate oral medications, switch to an appropriate oral follow-on treatment.
Participant ID: [Redacted]

### Day 0 Artesunate Dosing

1. Dosing date (dd/mo/yyy): ___/_____/_____
2. Participant’s weight: ________ kg
3. Dose ordered: _________ mg
4. Dosing start time (hh:mm): ___:___; Dosing stop time (hh:mm): ___:___
5. Did participant receive the entire dose?
   - Yes
   - No; Total amount received: _________ ml
     Record the reason the full dose was not received: __________________________

### 12 hour dose

Was participant dosed? □ Yes (complete below) □ No; reason not dosed: __________________________ (section is complete)

1. Dosing date (dd/mo/yyy): ___/_____/_____
2. Dose ordered: _________ mg
3. Dosing start time (hh:mm): ___:___; Dosing stop time (hh:mm): ___:___
4. Did participant receive the entire dose?
   - Yes
   - No; Total amount received: _________ ml
     Record the reason the full dose was not received: __________________________

### 24 hour dose

Was participant dosed? □ Yes (complete below) □ No; reason not dosed: __________________________ (section is complete)

1. Dosing date (dd/mo/yyy): ___/_____/_____
2. Dose ordered: _________ mg
3. Dosing start time (hh:mm): ___:___; Dosing stop time (hh:mm): ___:___
4. Did participant receive the entire dose?
   - Yes
   - No; Total amount received: _________ ml
     Record the reason the full dose was not received: __________________________
Participant ID: □□□□□□

48 hour dose

Was participant dosed? □ Yes (complete below) □ No; reason not dosed: ____________________________ (section is complete)

1. Dosing date (dd/mm/yyyy): _____/______/_____

2. Dose ordered: _____________ mg

3. Dosing start time (hh:mm): _____:____; Dosing stop time (hh:mm): _____:____

4. Did subject receive the entire dose?
   □ Yes
   □ No; Total amount received: ________________ ml
      Record the reason the full dose was not received: ____________________________
Participant ID: □□□□□

Follow-on dosing

1. Was the participant dosed sequentially with an oral agent?
   □ Yes (complete below) □ No, reason not dosed: ________________________________

Check medication given (check one): □ Malarone □ Doxycycline □ Mefloquine
□ Clindamycin (children under 8 years or pregnant women)

Complete dosing information in table below. Cross through, initial and date any rows not needed.

<table>
<thead>
<tr>
<th>Date of dosing (dd/month/yyyy)</th>
<th>Time of dosing (hh:mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
<tr>
<td><strong>/</strong>/<strong>/</strong>/<strong>/</strong>/__</td>
<td><strong>:</strong></td>
</tr>
</tbody>
</table>
Participant ID: □□□□□

1. Adjunctive and supportive treatments used (check all that apply):
   □ Blood transfusion
   □ Exchange transfusion
   □ Intubation
   □ Dialysis
   □ Vasopressors
   □ Other (specify):

Malaria Microscopy

Record all smears for the participant in the tables below. Cross through, initial and date any portion of the page not needed.
If a smear was performed, do not leave any rows of the table blank - Record ‘0’ for those smears where parasites are not present.

Date drawn: __/___/_____; Time drawn: __:___
  dd mon yyyy    hh mm

<table>
<thead>
<tr>
<th>Parasite Species</th>
<th>% Parasitemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. falciparum</td>
<td></td>
</tr>
<tr>
<td>P. vivax</td>
<td></td>
</tr>
<tr>
<td>P. ovale</td>
<td></td>
</tr>
<tr>
<td>P. malariae</td>
<td></td>
</tr>
</tbody>
</table>

Date drawn: __/___/_____; Time drawn: __:___
  dd mon yyyy    hh mm

<table>
<thead>
<tr>
<th>Parasite Species</th>
<th>% Parasitemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. falciparum</td>
<td></td>
</tr>
<tr>
<td>P. vivax</td>
<td></td>
</tr>
<tr>
<td>P. ovale</td>
<td></td>
</tr>
<tr>
<td>P. malariae</td>
<td></td>
</tr>
</tbody>
</table>

Date drawn: __/___/_____; Time drawn: __:___
  dd mon yyyy    hh mm

<table>
<thead>
<tr>
<th>Parasite Species</th>
<th>% Parasitemia</th>
</tr>
</thead>
<tbody>
<tr>
<td>P. falciparum</td>
<td></td>
</tr>
<tr>
<td>P. vivax</td>
<td></td>
</tr>
<tr>
<td>P. ovale</td>
<td></td>
</tr>
<tr>
<td>P. malariae</td>
<td></td>
</tr>
</tbody>
</table>
Laboratory Results
Record at least 1 set of laboratory results during or within 8 hours of completion of IV artesunate treatment. If labs are drawn on multiple days, select the lab values drawn closest to administration of the last dose.

<table>
<thead>
<tr>
<th>Lab</th>
<th>Value</th>
<th>Unit</th>
<th>Date drawn (dd/mo/yy)</th>
<th>Time drawn (hh:mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>g/dL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Hematocrit</td>
<td>%</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Platelets</td>
<td>/uL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>White blood cells</td>
<td>/uL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Chloride</td>
<td>mEq/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>BUN</td>
<td>mg/dL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Creatinine</td>
<td>mg/dL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Glucose</td>
<td>mg/dL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Lactate dehydrogenase (LDH)</td>
<td>U/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>AST</td>
<td>U/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>ALT</td>
<td>U/L</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td>Bilirubin, total</td>
<td>mg/dL</td>
<td></td>
<td>/ / /</td>
<td>:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Participant ID:</strong></td>
<td>□□□□□□□</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>End of Trial</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td><strong>End date</strong> <em>(dd/month/yyyy):</em></td>
<td>____<strong>/</strong><em><strong><strong>/</strong></strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2</td>
<td><strong>Did subject complete treatment?</strong></td>
<td>□ Yes □ No <em>(complete below)</em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Check one primary reason the participant did not complete the treatment:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Adverse event (AE)/Serious adverse event (SAE)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Death</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Withdrawal of consent <em>(check one)</em> □ Investigator request □ Participant request</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Lost to follow-up</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>□ Other; specify reason: _______________________________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Complete ‘End date’ as follows:

<table>
<thead>
<tr>
<th><strong>If participant</strong></th>
<th><strong>Record date as</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Completed through day XX</td>
<td>Day XX visit date</td>
</tr>
<tr>
<td>Discontinued due to AE/SAE</td>
<td>Date it was determined to discontinue due to AE/SAE</td>
</tr>
<tr>
<td>Died</td>
<td>Date of death</td>
</tr>
<tr>
<td>Withdrawal of consent</td>
<td>Date of withdrawal (either investigator request or subject request)</td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>Date of last contact with subject (telephone call, office visit, etc)</td>
</tr>
<tr>
<td>Other</td>
<td>Date of ‘Other’ event</td>
</tr>
</tbody>
</table>

I have reviewed all case report forms and attest that the data contained in them is accurate and complete.

__________________________________________________________________________

Clinician’s Signature | Date Signed *(dd/month/yyyy)*
APPENDIX III

Participant ID: □□□□

**Adverse Event Reporting** (make multiple copies of this page if required)
Record Serious Adverse Events (AE) reported/observed for the participant OR Check if None □ (form is complete)

For all AEs:
Fill out this form and fax or email it to the CDC Malaria Branch (fax: 404-718-4815; email: ktan@cdc.gov) or mail it to the CDC Malaria Branch (Address: 1600 Clifton Road NE, MS A-06, Atlanta, GA 30333) within 10 calendar days from the AE.

If serious adverse events (SAEs) occur: Notify CDC **within 24 hours** by telephone. Call the CDC Malaria Hotline at 770-488-7788 from 9:00am to 5:00 pm Eastern time; after hours call the CDC Emergency Operations Center at 770-488-7100. Ask to speak with the malaria clinician on call.

<table>
<thead>
<tr>
<th>Adverse event name &amp; description (see supplemental form below if hemolysis)</th>
</tr>
</thead>
</table>

### Severity
- □ Mild
- □ Moderate
- □ Severe

### Was this an SAE? □ No □ Yes

**If yes, specify:**
- □ 1. Death
- □ 2. Life-threatening
- □ 3. Persistent or symptomatic disability or incapacity
- □ 4. Hospitalization or prolongation of hospitalization
- □ 5. Congenital anomaly or birth defect
- □ 6. Other important medical event

### Date and Time of Onset
Date: ___________ Time: ___________

### Date and Time of Resolution
Date: ___________ Time: ___________

### Relationship to:
- Artesunate
  - □ Not Related
  - □ Unlikely
  - □ Possible
  - □ Probable
  - □ Definite
- Follow-on drug
  - □ Not Related
  - □ Unlikely
  - □ Possible
  - □ Probable
  - □ Definite

### Action taken with artesunate due to AE
- □ None
- □ Dosing changed: describe ____________
- □ Dosing temporarily interrupted: describe ____________
- □ Artesunate permanently discontinued

### Did AE require treatment? □ No □ Yes

### Outcome
- □ Recovered
- □ Ongoing
- □ Resolved with residual effects
- □ Death

### Concurrent medications at time of event
List all with start and stop dates (dd/mo/yy):

### Notes
Supplemental Adverse Event Form for Delayed Hemolysis

If hemolysis occurs 7-28 days after treatment with IV artesunate, provide the following laboratory values at hemoglobin nadir:

<table>
<thead>
<tr>
<th>Lab</th>
<th>Value</th>
<th>Unit</th>
<th>Date drawn (dd/month/yyyy)</th>
<th>Time drawn (hh:mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin</td>
<td>g/dL</td>
<td></td>
<td><strong>/</strong>/______</td>
<td><strong><strong>:</strong></strong></td>
</tr>
<tr>
<td>Reticulocytes</td>
<td>%</td>
<td></td>
<td><strong>/</strong>/______</td>
<td><strong><strong>:</strong></strong></td>
</tr>
<tr>
<td>Haptoglobin</td>
<td>mg/dL</td>
<td></td>
<td><strong>/</strong>/______</td>
<td><strong><strong>:</strong></strong></td>
</tr>
<tr>
<td>Lactate dehydrogenase (LDH)</td>
<td>U/L</td>
<td></td>
<td><strong>/</strong>/______</td>
<td><strong><strong>:</strong></strong></td>
</tr>
<tr>
<td>Bilirubin, total</td>
<td>mg/dL</td>
<td></td>
<td><strong>/</strong>/______</td>
<td><strong><strong>:</strong></strong></td>
</tr>
</tbody>
</table>
Appendix IV

List of CDC Quarantine Stations that stock Artesunate

Artesunate will be stored at the CDC Drug Service at CDC Headquarters in Atlanta, as well as in CDC Quarantine Stations. Current Quarantine Stations that stock artesunate are listed below, with their jurisdiction for artesunate delivery.

1. CDC Atlanta Quarantine Station
   Hartsfield International Airport
   Ph: (404) 639-1220;
   Jurisdiction: Georgia, Alabama, Mississippi, North Carolina, South Carolina, and Tennessee.

2. CDC Chicago Quarantine Station
   O'Hare International Airport
   Ph: (773) 894-2960;
   Jurisdiction: Illinois, Indiana, Iowa, Nebraska, South Dakota, North Dakota, Minnesota, Michigan, Ohio, Kentucky, and Wisconsin.

3. CDC Honolulu Quarantine Station
   Honolulu International Airport
   Ph: (808) 861-8530;
   Jurisdiction: Hawaii, Guam, and Pacific Trust Territories.

4. CDC Houston Quarantine Station
   George Bush Intercontinental Airport (IAH)
   Ph: (281) 230-3874
   Jurisdiction: Texas, New Mexico, Kansas, Missouri, Arkansas, Louisiana, and Oklahoma.

5. CDC Los Angeles Quarantine Station
   Tom Bradley International Airport
   Ph: (310) 215-2365;
   Jurisdiction: Southern California (Los Angeles, Orange, San Bernardino, Riverside, Ventura, Santa Barbara, and San Luis Obispo counties), Colorado, and Arizona.

6. CDC Miami Quarantine Station
   Miami International Airport
   Ph: (305) 526-2910;
   Jurisdiction: Florida, Puerto Rico and the Virgin Islands.

7. CDC New York Quarantine Station
   JFK International Airport
   Ph: (718) 553-1685;

8. CDC San Francisco Quarantine Station  
San Francisco International Airport  
Ph: (650) 876-2872;  
Jurisdiction: Central and Northern California (46 counties), Nevada, Utah, and Wyoming.

9. CDC Seattle Quarantine Station  
Seattle-Tacoma International Airport  
Ph: (206) 553-4519;  
Appendix V

PARTICIPANT CONSENT / PARENTAL PERMISSION FORM

Flesch-Kincaid 7.6 (without title and signature block)

You or your child are being asked to take part in this treatment program because you or your child have severe malaria. Severe malaria is the most serious form of malaria, which one gets through the bite of an infected mosquito. Usually, this type of bite happens while traveling in a part of the world that has the malaria parasite. Severe malaria can lead to many problems including coma, kidney and lung trouble, anemia (low red blood cells), and death.

This treatment program is sponsored by the Centers for Disease Control and Prevention (CDC). This program will use the drug artesunate to treat your severe malaria. Artesunate is an investigational drug. This means that artesunate has not been approved by the Food and Drug Administration (FDA) to treat malaria in the United States (U.S.). You or your child are being asked to take artesunate because you or your child have severe malaria.

Intravenous (IV) (by vein) artesunate has been used in many other parts of the world to treat severe malaria. Before deciding whether to take part, we want you or your child to know about the program.

This is a consent form. It gives information about this program. The program staff will talk with you or your child about this information. You or your child are free to ask questions at any time. Taking part in this program is voluntary. You or your child may leave this program at any time. If you or your child decide not to take part in or to stop this program, it will not affect the medical care you or your child would normally get. If you or your child agree to take part in this program, you will be asked to sign this consent form. You will get a copy to keep.

WHAT WILL HAPPEN TO ME?
We will take blood for tests to count the number of parasites (germs) in your or your child’s blood at the start of treatment and then every 12 hours.

We will ask you or your child about drugs you or your child are taking, any allergies, and your or your child’s health.

We will give you or your child artesunate by vein. Then we will watch you or your child for about 30 minutes to make sure that you or your child don’t have an allergic reaction to artesunate. If any allergic reactions or other side effects are seen, you or your child will be treated. Costs for hospital and medical care will not be covered by the CDC and will need to be paid by you, your insurer, Medicare, or Medicaid.

We will give you or your child doses of artesunate by vein every day for 3 days. Then we will switch you or your child to another medicine that you or your child can take by mouth.
If we cannot make the switch from medicine by vein to medicine by mouth because you or your child cannot take medicines by mouth, we will continue giving you or your child medicines by vein as needed; but you or your child will not receive artesunate for more than 7 days.

HOW MANY PEOPLE WILL TAKE PART IN THIS TREATMENT PROGRAM?
We do not know how many people will need artesunate to treat severe malaria.

ARE THERE BENEFITS?
By taking artesunate, you or your child may be cured of severe malaria.

ARE THERE RISKS?
Most people do not have serious problems when they take artesunate. There are rare reports of people developing anemia (low red blood cells) up to one month after they take artesunate. There is a chance that you or your child will have side effects, including an allergic reaction. When we draw blood for tests, or when we inject drugs by vein, there is a chance that this may cause pain, bleeding, or bruises where the needle enters the skin. In rare cases, needle sticks may cause fainting or infection.

WHAT ARE THE OTHER CHOICES BESIDES THIS PROGRAM?
There are no other FDA-approved IV drugs available for severe malaria.

WHAT IF I AM PREGNANT?
We do not know enough about artesunate to be sure that it will not cause harm to pregnant women and their babies. However, one recent study that included 183 pregnant women with malaria found that artesunate did not seem to cause miscarriages or congenital malformations. Also, malaria in itself can be harmful to the pregnant woman and her baby. You and your doctor will have to weigh the risks and benefits of taking artesunate, for you and your baby, if you are pregnant.

WHAT ABOUT PRIVACY?
We will keep all information about you or your child as private as the law allows. People who work at CDC and FDA may look at your medical records. Your or your child’s name and personal information will not be used or listed in reports or articles in magazines or journals. However, FDA rules say that CDC has to follow certain laws and rules to give this drug to you or your child. Your or your child’s doctor has to give CDC a report about your or your child’s response to treatment with artesunate. This is necessary because CDC has to report to FDA about the safety of artesunate. If more details about your or your child’s treatment course are needed, your or your child’s doctor might have to give CDC a copy of your or your child’s medical records. Your or your child’s doctor may contact you in the future to obtain follow up information that could be shared with CDC, FDA and the company that makes artesunate are allowed to look at CDC’s files about participants treated with this drug. Also, CDC is allowed to give your or your child’s name to public health or medical people who, for example, need to find out how you or your child got the infection and how to prevent other cases.

VOLUNTARY PARTICIPATION
It is your choice to take artesunate or for your child to be treated under this protocol.

- You may refuse or stop treatment at any time.
• You or your child will not lose any rights to get other health care by being in this program or by not being in this program.

WHAT IS THE COST OF THIS DRUG?
The drug will be given to you or your child free of charge. The other costs of the hospital and medical care are not covered by the CDC and will need to be paid by you, your or your child’s insurer, Medicare, or Medicaid.

WHAT HAPPENS IF I AM HARMED?
If you are hurt from being in this program, treatment will be given by the medical staff at your or your child’s hospital. CDC does not normally pay for harm done to you or your child as a result of being in a treatment program. Thus, you, your or your child’s insurer, Medicare, or Medicaid will have to pay for any care that is needed. However, by signing this consent form and agreeing to be in this program, you or your child are not giving up any of your or your child’s rights.

WHO CAN I CALL IF I HAVE PROBLEMS OR QUESTIONS?
If you have any questions about this program, you may talk with your doctor, Dr. ___________ at the following phone number ______________ or with Dr. Kathrine Tan (at 404.718.4701). You may talk with the available CDC malaria doctor at either 770-488-7788 or 770-488-7100. If you feel that you or your child have been harmed please contact Dr. Kathrine Tan (at 404.718.4701). If you have questions about your or your child’s rights as a participant in this program, please contact CDC’s Human Research Protection Office at (800)584-8814. Please leave a message that includes your name and telephone number, and refer to CDC protocol # 5032.
CONSENT STATEMENT

I have read the form or it has been read to me. I have been given a chance to ask questions and my questions have been answered. I agree to get or for my child to get intravenous artesunate to help treat severe malaria.

Print Participant/Parent Name: ____________________________________________

Participant/Parent Signature: ___________________________ Date: ____________

Legally Authorized Representative Signature: ___________________ Date: __________

Witness Signature: ___________________________ Date: ______________

(If applicable) I have translated this form into the __________________________ language.

Translator’s Signature: ___________________________ Date: ______________

NOTE: If participant is unable to sign, next of kin or legal guardian may sign.
NOTE: The participant will be offered a copy of the consent form.

If participant gives verbal consent, but is unable to sign and next of kin or legal guardian is not available, the patient should give his/her mark (either an “X” or a thumbprint), and the consenting physician should complete the following:

I, (Print Physician’s Name) ____________________________________________ certify that the above named participant has read this document or had it read to them, is unable to sign the document, and has verbally consented to participate. I further certify that a next of kin or a legal guardian who could sign for the participant is not readily available.

Physician’s Signature: ___________________________ Date: ____________

IF OBTAINING INFORMED CONSENT IS NOT FEASIBLE:

In the event that obtaining informed consent is not feasible because the patient is unable to respond and make wishes known about artesunate treatment and no legal guardian or next of kin is present the following provides for the treating physician to make a clinical determination to treat with artesunate provided that the treating physician and an independent physician certifies to the following within 2 working days of treating the patient with artesunate:

1. Patient is confronted by a life-threatening situation necessitating the use of artesunate
2. Informed consent cannot be obtained from the patient because of an inability to communicate with, or obtain legally-effective consent from, the patient.
3. Time is not sufficient to obtain consent from the patient’s legal representative.
4. There is no available alternative method of approved or generally recognized
therapy that provides an equal or greater likelihood of saving the life of the patient.

☐ Document as such in the patient's medical record and ensure the patient or patient's legally authorized representative is made aware that investigational artesunate was administered.

☐ Name & signature of treating physician who made the determination to administer artesunate to patient when informed consent could not be obtained:

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
</table>

☐ Name & signature of second physician, who is not otherwise participating in this treatment protocol, reviewing and evaluating decision to administer artesunate to patient:

<table>
<thead>
<tr>
<th>Name</th>
<th>Signature</th>
<th>Date</th>
</tr>
</thead>
</table>

☐ Return copy of this signed page to CDC